Edward Chu, MD; Hans-Joachim Scholl, MD, PhD; and Nadia Harbeck, MD, PhD, are highlighted.
On October 1, Edward Chu, MD, began his role as director ofAlbert Einstein Cancer Center and vice president for cancer medicine at Montefiore Medicine, both in New York, NY. He also became a professor of cancer medicine at Einstein and a professor of medicine and molecular pharmacology at Montefiore. Previously, Chu was the deputy director of the University of Pittsburgh Medical Center's Hillman Cancer Center in Pennsylvania. His research focuses on understanding the molecular mechanisms underlying drug resistance. He is also involved in developing novel agents for colorectal cancer and other gastroenterological malignancies.
The European Society for Medical Oncology (ESMO) bestowed its ESMO Award upon Hans-Joachim Schmoll, MD, PhD, during the ESMO Virtual Congress 2020, held September 19–21. The award recognizes his clinical work on colorectal and germline cancers, including his role in developing various treatment guidelines. Schmoll is the head of the Clinical Oncology Research division at the University Clinic of Martin Luther University in Halle, Germany. He authored the first ESMO consensus recommendations for patients with metastatic colorectal cancer.
Also at the ESMO Virtual Congress, Nadia Harbeck, MD, PhD, received the ESMO Lifetime Achievement Award for her contributions to breast cancer research and treatment. Her work has centered on personalizing treatment for breast cancer, and she has led several phase III trials exploring predictive biomarkers. Harbeck is the head of the Breast Center at the Ludwig Maximilian University Munich in Germany, where she also serves as chair for Conservative Oncology in the department of Obstetrics and Gynecology.
For more news on cancer research, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.